JP2019519572A - Ｃｏｐｄを処置するための組成物および方法 - Google Patents

Ｃｏｐｄを処置するための組成物および方法 Download PDF

Info

Publication number
JP2019519572A
JP2019519572A JP2018568253A JP2018568253A JP2019519572A JP 2019519572 A JP2019519572 A JP 2019519572A JP 2018568253 A JP2018568253 A JP 2018568253A JP 2018568253 A JP2018568253 A JP 2018568253A JP 2019519572 A JP2019519572 A JP 2019519572A
Authority
JP
Japan
Prior art keywords
hydroxyacetoxy
cyclopentyl
phenyl
methylpyrrolidinium
carboxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018568253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519572A5 (enExample
Inventor
ニコラス エス． ボドール，
ニコラス エス． ボドール，
Original Assignee
ボドール ラボラトリーズ， インコーポレイテッド
ボドール ラボラトリーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボドール ラボラトリーズ， インコーポレイテッド, ボドール ラボラトリーズ， インコーポレイテッド filed Critical ボドール ラボラトリーズ， インコーポレイテッド
Publication of JP2019519572A publication Critical patent/JP2019519572A/ja
Publication of JP2019519572A5 publication Critical patent/JP2019519572A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018568253A 2016-07-01 2017-06-30 Ｃｏｐｄを処置するための組成物および方法 Pending JP2019519572A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662357711P 2016-07-01 2016-07-01
US201662357730P 2016-07-01 2016-07-01
US62/357,730 2016-07-01
US62/357,711 2016-07-01
PCT/US2017/040348 WO2018006001A1 (en) 2016-07-01 2017-06-30 Compositions and methods for treatment of copd

Publications (2)

Publication Number Publication Date
JP2019519572A true JP2019519572A (ja) 2019-07-11
JP2019519572A5 JP2019519572A5 (enExample) 2020-08-06

Family

ID=60787597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568253A Pending JP2019519572A (ja) 2016-07-01 2017-06-30 Ｃｏｐｄを処置するための組成物および方法

Country Status (5)

Country Link
US (1) US20190224164A1 (enExample)
EP (1) EP3478365A4 (enExample)
JP (1) JP2019519572A (enExample)
CA (1) CA3029621A1 (enExample)
WO (1) WO2018006001A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027574A1 (ko) * 2018-07-31 2020-02-06 한국 한의학 연구원 나한과 추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
WO2021207729A1 (en) * 2020-04-10 2021-10-14 Mubarak Kamal Khan Compositions and methods for modulating ace2 receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515889A (ja) * 2005-11-10 2009-04-16 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399861B2 (en) * 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
AU2014227923B2 (en) * 2013-03-15 2019-02-14 Bodor Laboratories, Inc. Method of dosing and use of soft anticholinergic esters
JP2017507959A (ja) * 2014-03-13 2017-03-23 ボドール ラボラトリーズ， インコーポレイテッド 選択された抗コリン作動性両性イオンの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515889A (ja) * 2005-11-10 2009-04-16 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル

Also Published As

Publication number Publication date
EP3478365A1 (en) 2019-05-08
WO2018006001A1 (en) 2018-01-04
CA3029621A1 (en) 2018-01-04
US20190224164A1 (en) 2019-07-25
EP3478365A4 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
JP5816631B2 (ja) ムスカリン受容体拮抗薬およびβ２アドレナリン受容体作動薬の組み合わせ
JP2019038818A (ja) 医薬組成物
EP1957451B1 (en) Soft anticholinergic zwitterions
JP2018168172A (ja) ロフルミラストｎ−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法
JP2006519204A (ja) 高効能の持続性ベータ２−アゴニストを他の活性成分と組み合わせて含んでなる薬剤
CA2575932A1 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
US20090181935A1 (en) Compositions comprising an antimuscarinic and a long-acting beta-agonist
US20100261690A1 (en) Novel combinations
JP2022520990A (ja) 呼吸器疾患の治療の方法
AU2015261103A1 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD
EP1948596B1 (en) Soft anticholinergic esters
US20110124613A1 (en) Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
JP2019519572A (ja) Ｃｏｐｄを処置するための組成物および方法
US9795561B2 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2010097114A1 (en) Novel combination of therapeutic agents
JP2007524699A (ja) ロフルミラストとグリコピロニウムとの組合せ物
FI4199922T3 (fi) (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa
JP2016504358A (ja) オキシブチニンを投与するための方法および組成物
US20070071689A1 (en) Advantageous combination for inhalation of nacystelyn and bronchodilators
WO2010008341A1 (en) A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
WO2009142568A1 (en) Combination of (a) glucocorticoid receptor modulator and (b) a b2-agonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208